Erdafitinib in locally advanced or metastatic urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Quinoxalines
  • Receptors, Fibroblast Growth Factor
  • Urologic Neoplasms

abstract

  • A total of 99 patients in the selected-regimen group received a median of five cycles of erdafitinib. Of these patients, 43% had received at least two previous courses of treatment, 79% had visceral metastases, and 53% had a creatinine clearance of less than 60 ml per minute. The rate of confirmed response to erdafitinib therapy was 40% (3% with a complete response and 37% with a partial response). Among the 22 patients who had undergone previous immunotherapy, the confirmed response rate was 59%. The median duration of progression-free survival was 5.5 months, and the median duration of overall survival was 13.8 months. Treatment-related adverse events of grade 3 or higher, which were managed mainly by dose adjustments, were reported in 46% of the patients; 13% of the patients discontinued treatment because of adverse events. There were no treatment-related deaths.

publication date

  • July 25, 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1817323

PubMed ID

  • 31340094

Additional Document Info

start page

  • 338

end page

  • 348

volume

  • 381

number

  • 4